6perAI is an AI-powered decision intelligence platform that helps healthcare systems optimize drug spend by measuring real-world therapeutic persistence.

It enables procurement and payer stakeholders to move beyond acquisition price and make decisions based on real clinical and economic outcomes.

Healthcare systems invest millions in therapies without visibility on their real-world performance after procurement.

6perAI uncovers hidden inefficiencies such as early discontinuation, therapy switching and avoidable spend — enabling smarter allocation of healthcare budgets.

Therapeutic persistence is the duration of time a patient remains on a treatment, from initiation to clinician-documented discontinuation.

It is a key indicator of how well a therapy performs in real-world conditions.

Persistence is a direct proxy for real-world value.

A lower-cost therapy with poor persistence often leads to higher total cost due to switching, complications and additional treatments.

6perAI enables procurement teams to identify which therapies truly deliver value over time.

6perAI is designed for healthcare decision-makers, including:

• Procurement leaders
• Hospital and regional payers
• Healthcare system administrators

It is particularly relevant for organizations managing high-cost therapies and seeking to improve cost-effectiveness.

6perAI allows decision-makers to compare therapies based on real-world performance and cost efficiency — not just acquisition price.

This enables more informed, value-based procurement strategies.

Yes.

By identifying therapies that deliver better real-world outcomes, 6perAI enables healthcare systems to:

• Reduce avoidable spend
• Reallocate budgets more efficiently
• Treat more patients within the same budget

6perAI provides independent, real-world evidence on therapy performance, strengthening the position of procurement and payer stakeholders.

It shifts conversations from price-based discussions to value-based negotiations focused on outcomes.

6perAI works with existing hospital data — primarily prescribing and dispensing records.

It requires no additional data collection and minimal operational effort.

No.

6perAI is designed for rapid deployment and works with existing datasets, minimizing IT complexity and accelerating time to value.

Yes.

6perAI supports on-premise deployment, ensuring that patient data remains within each hospital and complies with local data governance and privacy regulations.

A typical proof of concept delivers actionable insights in just 4–6 weeks.

This allows healthcare organizations to quickly validate impact and start optimizing procurement decisions.

A proof of concept typically includes:

• Analysis of a specific disease area
• Comparison of therapies
• Persistence evaluation
• Budget impact analysis
• Actionable procurement recommendations

While results vary by disease area, 6perAI typically identifies significant inefficiencies in drug spend.

This enables measurable savings and improved patient coverage within a short timeframe.

Yes.

6perAI is highly aligned with the strategic priorities of healthcare systems in the Gulf region and American countries

 , including:

• Value-based healthcare
• Centralized procurement
• Budget sustainability
• Expanding patient access

It is particularly relevant for markets such as UAE, Saudi Arabia and Qatar.

The first step is a structured discussion to understand your priorities and identify a high-impact use case.

From there, a tailored proof of concept can be launched to demonstrate measurable value in a matter of weeks.